Comparison of the novel CompEx asthma exacerbation endpoint to the ATS/ERS adapted moderate/severe asthma exacerbation definition used in the MITRA trial

Respir Med. 2019 Jul:153:1-2. doi: 10.1016/j.rmed.2019.04.014. Epub 2019 May 1.

Authors

Göran Eriksson¹, Hendrik Nolte², Christian Ljørring³, Bente Riis⁴, Johann Christian Virchow⁵

Affiliations

¹ Department of Respiratory Medicine and Allergology, Lund University Hospital, Lund, Sweden.
² ALK, USA.
³ ALK, Hørsholm, Denmark.
⁴ ALK, Hørsholm, Denmark. Electronic address: clinicaltrials@alk.net.
⁵ Department of Pneumology/Intensive Care Medicine, University of Rostock, Germany.

PMID: 31136926
DOI: 10.1016/j.rmed.2019.04.014

No abstract available

Publication types

Clinical Trial, Phase III
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / administration & dosage
Adrenal Cortex Hormones / therapeutic use
Animals
Asthma / drug therapy*
Asthma / physiopathology
Asthma / prevention & control
Desensitization, Immunologic / methods
Disease Progression
Humans
Peak Expiratory Flow Rate / drug effects
Pyroglyphidae
Respiratory Therapy
Rhinitis / drug therapy*
Severity of Illness Index
Sublingual Immunotherapy / methods*
Treatment Outcome

Substances

Adrenal Cortex Hormones